The Boston Scientific Antiproliferative, Paclitaxel Eluting Stents (TAXUS)

2001 ◽  
pp. 311-319 ◽  
Author(s):  
Sigmund Silber ◽  
Eberhard Grube
Keyword(s):  
Boston Scientific

Coronary Intervention with the Excimer Laser: Review of the Technology and Outcome Data

2016 ◽  
Vol 11 (1) ◽  
pp. 27
Author(s):  
John Rawlins ◽  
◽  
◽  
◽  
◽  
...  
Keyword(s):  
Excimer Laser ◽  
Coronary Intervention ◽  
Outcome Data ◽  
Boston Scientific ◽  
Technical Aspects ◽  
Safety And Efficacy ◽  
Percutaneous Coronary ◽  
Short Period ◽  
Complex Lesions

Excimer laser coronary atherectomy (ELCA) is a long-established adjunctive therapy that can be applied during percutaneous coronary intervention (PCI). Technical aspects have evolved and there is an established safety and efficacy record across a number of clinical indications in contemporary interventional practice where complex lesions are routinely encountered. The role of ELCA during PCI for thrombus, non-crossable or non-expandable lesions, chronic occlusions and stent under-expansion are discussed in this review. The key advantage of ELCA over alternative atherectomy interventions is delivery on a standard 0.014-inch guidewire. Additionally, the technique can be mastered by any operator after a short period of training. The major limitation is presence of heavy calcification although when rotational atherectomy (RA) is required but cannot be applied due to inability to deliver the dedicated RotaWire™ (Boston Scientific), ELCA can create an upstream channel to permit RotaWire passage and complete the case with RA – the RASER technique.

scholarly journals A novel technique for stenting in cases of refractory intracranial stenosis

2020 ◽  
Vol 26 (3) ◽  
pp. 337-340
Author(s):  
Hugo Cuellar ◽  
James Barry ◽  
Rimal Hanif
Keyword(s):  
Medical Management ◽  
Intracranial Stenosis ◽  
Boston Scientific ◽  
Single System ◽  
Endovascular Management ◽  
Novel Technique ◽  
Angioplasty Balloon ◽  
Improved Outcomes ◽  
Previous Level ◽  
Level 1

Endovascular management of intracranial stenosis is one of the most controversial subjects in neurointervention. Previous level 1 evidence shows superiority of medical management but more recent studies have shown improved outcomes in selective patients. We describe a case demonstrating a new method for stenting of intracranial stenosis using a single system with Coyote angioplasty balloon (Boston Scientific) and the Atlas stent (Stryker).

scholarly journals Rethinking MAC Clauses in the Time of Akorn, Boston Scientific, and COVID-19

2021 ◽  
pp. 241
Author(s):  
Samuel Shapiro
Keyword(s):  
Contract Law ◽  
Boston Scientific ◽  
Economic Uncertainty ◽  
The World ◽  
The Face

The MAC clause is perhaps the most important clause in contract law, giving acquirers the ability to terminate even the largest agreements in the face of an often vaguely defined “Material Adverse Change.” For decades, even though MAC clauses have been present in nearly every merger agreement, courts have almost universally refused to enforce them. But the Delaware Chancery Court’s 2018 decision in Akorn may finally change that. As the world deals with the economic uncertainty caused by COVID-19, courts may soon get more opportunities to decide whether or not they will follow Akorn’s lead and begin to allow companies to exit agreements. In this Article, I argue that they should.

Sign in / Sign up

Export Citation Format

Share Document